Resource Type

Journal Article 491

Year

2024 1

2023 31

2022 47

2021 46

2020 33

2019 43

2018 26

2017 34

2016 19

2015 28

2014 21

2013 26

2012 14

2011 22

2010 15

2009 24

2008 11

2007 14

2006 4

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 8

solar cell 6

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

stem cell 5

COVID-19 4

cell proliferation 4

control 4

lung cancer 4

microbial fuel cell 4

solid oxide fuel cell 4

cancer immunotherapy 3

chemotherapy 3

prognosis 3

solid oxide fuel cell (SOFC) 3

Apoptosis 2

Artificial intelligence 2

open ︾

Search scope:

排序： Display mode:

Fine-tuning cell organelle dynamics during mitosis by small GTPases

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 339-357 doi: 10.1007/s11684-022-0926-1

Abstract: Small GTPases belonging to the Ras superfamily regulate various cell organelles during division.Being the key regulators of membrane dynamics, the dysregulation of small GTPases is widely associatedRecent discoveries shed light on the molecular properties of small GTPases as sophisticated modulatorsThis review collects current knowledge on small GTPases in the regulation of cell organelles during mitosisand highlights the mediator role of small GTPase in transducing cell cycle signaling to organelle dynamics

Keywords： small GTPase     cell organelle     mitosis    

HTML PDF Collect

Discovery of small molecule degraders for modulating cell cycle

Frontiers of Medicine   Pages 823-854 doi: 10.1007/s11684-023-1027-5

Abstract: The cell cycle is a complex process that involves DNA replication, protein expression, and cell divisionDysregulation of the cell cycle is associated with various diseases.Cyclin-dependent kinases (CDKs) and their corresponding cyclins are major proteins that regulate the cell

Keywords： PROTAC     molecular glue     degrader     cell cycle     CDK     cyclin    

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint    

HTML PDF Collect

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract:

Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Frontiers of Medicine 2011, Volume 5, Issue 1,   Pages 53-60 doi: 10.1007/s11684-011-0121-2

Abstract: paper, we review the development of thoracoscopy, the present status of VATS for early stage of non-smallcell lung cancer (NSCLC), and comparison between VATS and open thoracotomy in the management of NSCLC

Keywords： non-small cell lung cancer     video-assisted thoracoscopic surgery     lobectomy    

HTML PDF Collect

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC (ns-NSCLC). However, the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation. Thus, 59 patients were included in the present retrospective study, 22 patients in the bevacizumab plus pemetrexed and platinum (B+PP) group, and 37 patients in the pemetrexed and platinum (PP) group. For the entire cohort of patients, the median OS was 33.3 months, and the 1-year and 2-year overall survival rates were 88.5% and 67.8%, respectively. The median OS and 1-year and 2-year OS rates were 20.5 months, 70.3% and 0%, respectively, in the B+PP group and 33.4 months, 97.0% and 89.4%, respectively, in the PP group (P <0.001). The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group (27.3% vs. 10.8%, respectively; P=0.204). Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS, whereas the addition of bevacizumab was an unfavorable prognostic factor. With increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 41-44 doi: 10.1007/s11684-009-0009-6

Abstract: This study aims to research the expression of spleen tyrosine kinase (Syk) in non-small cell lung cancerapplied to detect the expression of Syk and p53 protein in 39 cases of NSCLC (23 cases of lung squamous cell

Keywords： Syk kinase     carcinoma     non-small-cell lung     tumor suppressor protein p53    

HTML PDF Collect

Small cell carcinoma of the urinary bladder without gross hematuria: a case report

Wanqiu Huang,Yang Luan,Lu Jin,Tao Wang,Ruibao Chen,Zheng Liu,Zhiqiang Chen,Ruzhu Lan

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 384-387 doi: 10.1007/s11684-015-0405-z

Abstract:

Small cell carcinoma of the urinary bladder (SCCB) is a rare and aggressive form of bladder cancer

Keywords： carcinoma     small cell     urinary bladder neoplasms     diagnosis    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: EGFR) inhibitor osimertinib (OSI) has been approved as the first-line treatment for EGFR-mutant non-smallcell lung cancer (NSCLC).

Keywords： osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

HTML PDF Collect

Chemical transdifferentiation: closer to regenerative medicine

Aining Xu,Lin Cheng

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 152-165 doi: 10.1007/s11684-016-0445-z

Abstract:

Cell transdifferentiation, which directly switches one type of differentiated cells into another celltype, is more advantageous than cell reprogramming to generate pluripotent cells and differentiate themSmall molecules with compelling advantages are a potential alternative in manipulating cell fate conversiondevelopments in the research of small molecules in promoting cell conversion.closer to the clinical translation in cell therapy.

Keywords： cell therapy     cell transdifferentiation     chemical compounds     small molecules     tissue regeneration    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: In general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Frontiers of Medicine 2020, Volume 14, Issue 1,   Pages 60-67 doi: 10.1007/s11684-019-0694-8

Abstract: Moreover, C620-0696 was cytotoxic in BPTF with a high expression of non-small-cell lung cancer (NSCLCpartially inhibited the migration and colony formation of NSCLC cells owing to apoptosis induction and cellpresents an effective strategy to target a bromodomain factor-mediated tumorigenesis in cancers with small

Keywords： BPTF     small molecule     epigenetics     non-small-cell lung cancer    

HTML PDF Collect

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Frontiers of Medicine 2013, Volume 7, Issue 4,   Pages 462-476 doi: 10.1007/s11684-013-0270-6

Abstract: for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem celldemonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cellconditions from a non-small cell lung cancer cell line.00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell

Keywords： drug resistance     cancer stem cell     checkpoint kinase 1 (CHK1)     PF-00477736     lung cancer     tumorigenicity    

HTML PDF Collect

A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Eric C.H. Lai,Kam Man Chung,Stephanie H.Y. Lau,Wan Yee Lau

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 108-111 doi: 10.1007/s11684-014-0344-0

Abstract: intra-abdominal recurrence from a previously resected gastrointestinal stromal tumour (GIST) of the smallIn this patient who presented with spontaneous rupture of a small intestinal GIST, the novel use of targeted

Keywords： gastrointestinal stromal tumour     hemoperitoneum     small bowel GIST     small bowel neoplasm     imatinib    

HTML PDF Collect

Title Author Date Type Operation

Fine-tuning cell organelle dynamics during mitosis by small GTPases

Journal Article

Discovery of small molecule degraders for modulating cell cycle

Journal Article

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Journal Article

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Journal Article

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell

Journal Article

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Journal Article

Small cell carcinoma of the urinary bladder without gross hematuria: a case report

Wanqiu Huang,Yang Luan,Lu Jin,Tao Wang,Ruibao Chen,Zheng Liu,Zhiqiang Chen,Ruzhu Lan

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article

Chemical transdifferentiation: closer to regenerative medicine

Aining Xu,Lin Cheng

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Journal Article

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Journal Article

A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Eric C.H. Lai,Kam Man Chung,Stephanie H.Y. Lau,Wan Yee Lau

Journal Article